Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial

Results expected by end of 2020 JERUSALEM, Nov. 18, 2019 -- (Healthcare Sales &Marketing Network) -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficac... Biopharmaceuticals BiondVax Pharmaceuticals, influenza vaccine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Flu season in the U.S. is off to an early start—which means a virulent winter may be impending. Influenza activity has been higher than normal for four weeks in a row, which many experts consider the official mark of flu season. As of the week ending Nov. 30, 3.5% of visits to health care providers nationwide were related to influenza-like illness, according to the U.S. Centers for Disease Control and Prevention (CDC). Already, the country has seen about 1.7 million cases of the flu, 16,000 flu-related hospitalizations and 910 flu-related deaths, the CDC says. Six children have died so far. So far this year, flu act...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Infectious Disease Source Type: news
AbstractObjectivesPneumococcal and influenza vaccination rates have been suboptimal in studies of immunosuppressed patients. We aimed to assess barriers to and increase rates of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and influenza vaccination in this group. The primary endpoint was a statistically significant increase in adequate PPSV23 and influenza vaccination.MethodsIn 2017, rheumatology outpatients completed an anonymous questionnaire recording vaccination knowledge, status, and barriers. Simultaneously, a low-cost multifaceted quality improvement (QI) intervention was performed. All outpatients on oral...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
Publication date: Available online 6 December 2019Source: American Journal of Kidney DiseasesAuthor(s): Junichi Ishigami, Yingying Sang, Morgan E. Grams, Josef Coresh, Alex Chang, Kunihiro MatsushitaRationale &ObjectiveInfluenza vaccination is recommended for all adults but particularly for older adults and those with high-risk conditions. Reduced kidney function is an important high-risk condition, but the effectiveness of influenza vaccination across kidney function is uncharacterized. We assessed the effectiveness of influenza vaccination among older adults with and without reduced kidney function.Study DesignObserv...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
rečková E Abstract Influenza A viruses (IAVs) cause yearly repeating infections in humans. The current vaccination approach is based on the production of virus-neutralizing antibodies. Virus-neutralizing antibodies, however, are closely strain-specific due to the IAV variability. Therefore, antibodies produced during the previous influenza season do not provide sufficient protection against new infection, and, hence, annual revaccination is needed. The utilization of the influenza conserved stem domain of hemagglutinin (HA), the HA2 gp, led to a new vaccine design based on cross-reactive cellular and ...
Source: Acta Virologica - Category: Infectious Diseases Authors: Tags: Acta Virol Source Type: research
Authors: Laguna-Torres VA, Gómez J, Hernández H, Francia-Romero J, Bisso-Andrade A, Guerreros A, Cerna-Barco J, Sanchez-Vergaray E, Gotuzzo E Abstract The importance of surveilling the circulation of the influenza virus and timely vaccination of different populations in Peru was analyzed in three sessions by a group of clinical experts from different specialties. The Peruvian national influenza surveillance system has many selected establishments that have become currently ineffective in terms of a timely report. Most of the samples come from Lima. The viral distribution is inadequately analyzed. The ...
Source: Revista Peruana de Medicina de Experimental y Salud Publica - Category: International Medicine & Public Health Tags: Rev Peru Med Exp Salud Publica Source Type: research
In conclusion, this study suggests promoting initiatives for reducing absenteeism, identifying those factors that would facilitate it, and having a contingency plan prepared in the event of an influenza pandemic. PMID: 31800943 [PubMed - in process]
Source: Revista Peruana de Medicina de Experimental y Salud Publica - Category: International Medicine & Public Health Tags: Rev Peru Med Exp Salud Publica Source Type: research
Conditions:   Selenium Supplementation;   Influenza Vaccination Interventions:   Dietary Supplement: Selenium Supplementation;   Biological: Influenza vaccination Sponsors:   Huazhong University of Science and Technology;   The University of Queensland Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Computationally optimized broadly reactive Ags (COBRA) targeting H1 elicit a broad cross-reactive and cross-neutralizing Ab response against multiple H1N1 viral strains. To assess B cell breadth, Mus musculus (BALB/c) Ab-secreting cells elicited by a candidate COBRA hemagglutinin (HA) (termed P1) were compared with Ab-secreting cells elicited by historical H1N1 vaccine strains. In addition, to evaluate the Ab response elicited by P1 HA at increased resolution, a panel of P1 HA-specific B cell hybridomas was generated following immunization of mice with COBRA P1 and the corresponding purified mAbs were cha...
Source: Journal of Immunology - Category: Allergy & Immunology Authors: Tags: J Immunol Source Type: research
More News: Influenza | Influenza Vaccine | Marketing | Pharmaceuticals | Vaccines